Виктор Канде
Виктор Кадеу Куммео | |
|---|---|
| Национальность | Конголезский |
| Альма -матер | Университет Киншаса |
| Известен для | спящей болезни Исследование |
| Научная карьера | |
| Учреждения | Министерство здравоохранения Университет Киншаса |
Виктор Канде Бету Кумезо - конголезский врач, который является экспертом по африканскому трипаносомоза . Он работает в программе National De Lutte Contre La Trypanosomiase Humaine Africaine в Университете Киншасы .
Ранняя жизнь и образование
[ редактировать ]Канде изучала медицину. В возрасте 27 лет он был единственным врачом для 11 000 человек в провинции Бандунду . [ 1 ]
Исследовать
[ редактировать ]Канде известен как отец спящей болезни . Он был сделан директором Демократической Республики Программы Солания Конго и работает с Министерством общественного здравоохранения. [ 1 ] [ 2 ] Африканский трипаносомоз непропорционально влияет на людей в Демократической Республике Конго . [ 3 ] Болезнь вызвана трипаносомой бруси и обычно представляет в хронической форме. [ 4 ] Он исследует эпидемиологию спящей болезни. [ 5 ] Он был одним из первых, кто сообщил о возрождении сонной болезни, призывая к большей помощи, межстрановое сотрудничество и улучшение медицинских учреждений и вариантов лечения. [ 6 ]
Kande has been the principal investigator for several studies of new treatments for African trypanosomiasis.[7] He investigated the efficacy and safety of DB289, which is administered as a dication prodrug to Pentamidine. He also demonstrated a high failure rate with Melarsoprol and investigated the use of Pafuramidine.[8] In a country with few passable roads or hospitals, Kande and his colleagues recruited 400 people with late stage Trypanosoma brucei for a trial of Fexinidazole sponsored by the Drugs for Neglected Diseases initiative.[9][10] The study demonstrated that fexinidazole is an effective treatment for sleeping sickness.[11][12] The work was published in The Lancet and led to Kande being described by Richard Lehman (primary care physician) the 'true hero of medicine'.[10][11][12] Fexinidazole received a positive opinion from the European Medicines Agency under Article 58 in November 2018[13] and was registered in the Democratic Republic of Congo in December 2018.[14]
Kande is currently investigating SCYX-7158 (acoziborole) as a single-dose treatment for Human African Trypanosomiasis (HAT) in a clinical trial sponsored by the Drugs for Neglected Diseases initiative.[15][16]
He looks for innovative partnerships between the private and public sector, such as the partnership that led to the delivery of fexinidazole by DNDi.[17] In 2018 Kande was awarded the Anne Maurer Cecchini award of the Geneva Health Forum.[12]
References
[edit]- ^ Jump up to: a b Boseley, Sarah; Levene, David (2018-11-16). "The big sleep: how the world's most troubled country is beating a deadly disease". The Guardian. ISSN 0261-3077. Retrieved 2018-11-19.
- ^ Trypanosomiasis, WHO Expert Committee on the Control and Surveillance of Human African; Organization, World Health (2013). Control and Surveillance of Human African Trypanosomiasis: Report of a WHO Expert Committee. World Health Organization. ISBN 9789241209847.
- ^ "Human African trypanosomiasis in the Democratic Republic of the Congo: disease distribution and risk - Dimensions". Retrieved 2018-11-20.
- ^ Courtin, David; Jamonneau, Vincent; Mathieu, Jean-Francois; Koffi, Mathurin; Milet, Jacqueline; Yeminanga, Claude Sese; Kumeso, Victor Kande Betu; Cuny, Gerard; Bilengue, Constantin Miaka Mia (May 2006). "Comparison of cytokine plasma levels in human African trypanosomiasis". Tropical Medicine and International Health. 11 (5): 647–653. doi:10.1111/j.1365-3156.2006.01612.x. ISSN 1360-2276. PMID 16640617.
- ^ Simo, Gustave; Diabakana, Philemon; Betu Ku Mesu, Victor; Manzambi, Emile; Ollivier, Gaelle; Asonganyi, Tazoacha; Cuny, Gerard; Grebaut, Pascal (2006). "Human African Trypanosomiasis Transmission, Kinshasa, Democratic Republic of Congo". Emerging Infectious Diseases. 12 (12): 1968–1970. doi:10.3201/eid1212.060516. ISSN 1080-6040. PMC 3291358. PMID 17326955.
- ^ Van Nieuwenhove, Simon; Betu-Ku-Mesu, Victor Kande; Diabakana, Philemon Mansinsa; Declercq, Johan; Bilenge, Constantin Miaka Mia (May 2001). "Sleeping sickness resurgence in the DRC: the past decade". Tropical Medicine and International Health. 6 (5): 335–341. doi:10.1046/j.1365-3156.2001.00731.x. ISSN 1360-2276. PMID 11348528.
- ^ "Trial of DB289 for the Treatment of Stage I African Trypanosomiasis - Full Text View - ClinicalTrials.gov". Retrieved 2018-11-19.
- ^ Burri, Christian; Yeramian, Patrick D.; Allen, James L.; Merolle, Ada; Serge, Kazadi Kyanza; Mpanya, Alain; Lutumba, Pascal; Mesu, Victor Kande Betu Ku; Bilenge, Constantin Miaka Mia (2016-02-16). "Efficacy, Safety, and Dose of Pafuramidine, a New Oral Drug for Treatment of First Stage Sleeping Sickness, in a Phase 2a Clinical Study and Phase 2b Randomized Clinical Studies". PLOS Neglected Tropical Diseases. 10 (2): e0004362. doi:10.1371/journal.pntd.0004362. ISSN 1935-2735. PMC 4755713. PMID 26881924.
- ^ "Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2 - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. 17 February 2018. Retrieved 2019-07-29.
- ^ Jump up to: a b "Richard Lehman's journal review—13 November 2017 - The BMJ". The BMJ. 2017-11-13. Retrieved 2018-11-20.
- ^ Jump up to: a b Mesu, Victor Kande Betu Ku; Kalonji, Wilfried Mutombo; Bardonneau, Clélia; Mordt, Olaf Valverde; Blesson, Séverine; Simon, François; Delhomme, Sophie; Bernhard, Sonja; Kuziena, Willy (January 2018). "Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial". The Lancet. 391 (10116): 144–154. doi:10.1016/S0140-6736(17)32758-7. ISSN 0140-6736. PMID 29113731. S2CID 46781585.
- ^ Jump up to: a b c "Award Anne Maurer Cecchini | Geneva Health Forum 2018". Geneva Health Forum 2018. Retrieved 2018-11-19.
- ^ CZARSKA-THORLEY, Dagmara (2018-11-16). "CHMP recommends first oral-only treatment for sleeping sickness". European Medicines Agency. Retrieved 2019-07-29.
- ^ "Fexinidazole, the first all-oral treatment for sleeping sickness, approved in Democratic Republic of Congo | DNDi". Drugs for Neglected Diseases initiative (DNDi). 29 January 2019. Retrieved 2019-07-29.
- ^ "ASTMH 2018 – DNDi". www.dndi.org. Retrieved 2018-11-19.
- ^ "Prospective Study on Efficacy and Safety of SCYX-7158 in Patients Infected by Human African Trypanosomiasis Due to T.b. Gambiense - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2019-07-29.
- ^ "ASTMH 2018 – DNDi". www.dndi.org. Retrieved 2018-11-19.